Back
Compare AU
Compare BEAR vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Australian Equities Bear Complex ETF (BEAR) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
BEAR | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 73 |
Median incremental investment | $1,175.25 | $653.58 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,676.10 | $1,356.87 |
Average age group | 26 - 35 | > 35 |
Key Summary
BEAR | CURE | |
|---|---|---|
Strategy | BEAR.AX was created on 2012-07-06 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. BEAR.AX seeks to generate returns that are negatively correlated to the returns of the Australian sharemarket. The Fund expects to generate a positive return when the S&P/ASX Accumulation 200 Index falls (and a negative return when the index rises). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | SPI 200 FUTURES JUN25 (0 %) AUD - AUSTRALIA DOLLAR (53.44 %) BETASHARES AUSTRALIAN CASH PLUS FUND (24.23 %) | Insmed Inc (3.41 %) Alnylam Pharmaceuticals Inc (3.27 %) Natera Inc (3.00 %) |
Top 3 industries | Other (79.79 %) Communication Services (20.21 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 1.38 % | 0.45 % |
Key Summary
BEAR | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 1.38 % | 0.45 % |
Price | $7.55 | $43.77 |
Size | $39.345 million | $29.601 million |
10Y return | -54.93 % | N/A |
Annual distribution yield (5Y) | 0.69 % | 7.07 % |
Market | ASX | ASX |
First listed date | 09/07/2012 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
BEAR | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 73 |
Median incremental investment | $1,175.25 | $653.58 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,676.10 | $1,356.87 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
BEAR | CURE | |
|---|---|---|
Pros |
| |
Cons |
|
BEAR | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |